Granted Patent
B2
US 12,275,785 · App. 17/121,513 · Granted Apr 15, 2025
Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
Inventors:
Cristina De Min (Basel, CH); Walter Ferlin (Basel, CH); Fabrizio De Benedetti (Basel, CH)
Assignee:
Swedish Orphan Biovitrum AG
C07K16/249A61K9/0019A61K39/3955A61K45/06G01N33/6863A61K39/395A61K2039/505A61K2039/54A61K2039/545C07K2317/565C07K2317/76G01N2333/521G01N2800/24G01N2800/7095
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFNγ, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFNγ, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFNγ) signaling, including neutralizing anti-IFNγ antibodies.
Claims (10)
1. A method of alleviating a symptom of macrophage activation syndrome, the method comprising detecting a level of CXCL9, alone or in conjunction with one or more other biomarkers in a biological sample from a subject, comparing the detected level of CXCL9 to a control level of expression, and when the detected level is elevated, administering an anti-interferon gamma (IFNγ) antibody or immunologically active fragment thereof to the subject, wherein the anti-IFNγ antibody or immunologically active fragment thereof comprises a variable heavy chain (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SYAMS (SEQ ID NO: 1); a VH CDR2 comprising the amino acid sequence of AISGSGGSTYYADSVKG (SEQ ID NO: 2); a VH CDR3 comprising the amino acid sequence of DGSSGWYVPHWFDP (SEQ ID NO: 3); a variable light (VL) CDR1 comprising the amino acid sequence of TRSSGSIASNYVQ (SEQ ID NO: 4); a VL CDR2 comprising the amino acid sequence of EDNORPS (SEQ ID NO: 5); and a VL CDR3 comprising the amino acid sequence of QSYDGSNRWM (SEQ ID NO: 6).
2. The method of claim 1 , wherein the one or more other biomarkers is selected from the group consisting of total IFNγ level, CXCL10, CXCL11, and combinations thereof.
3. The method of claim 1 , wherein the biological sample is or is derived from blood.
4. The method of claim 1 , wherein the biological sample is serum.
5. The method of claim 1 , wherein the anti-IFNγ antibody or immunologically active fragment thereof comprises the heavy chain variable amino acid sequence of SEQ ID NO: 47 and the light chain variable amino acid sequence of SEQ ID NO: 48).
6. The method of claim 1 , wherein the anti-IFNγ antibody or immunologically active fragment thereof comprises the heavy chain amino acid sequence of SEQ ID NO: 44 and the light chain amino acid sequence of SEQ ID NO: 46.
7. The method of claim 1 , wherein the subject is human.
8. The method of claim 1 , wherein the disorder is MAS in the context of systemic Juvenile Idiopathic Arthritis (sJIA).
9. The method of claim 1 , wherein the disorder is MAS in the context of autoimmune disease or inflammatory disorder.
10. The method of claim 1 , wherein the disorder is MAS in the context of systemic lupus erythematosus (SLE).
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 2, 2021
From: DE MIN, CRISTINA; FERLIN, WALTER; DE BENEDETTI, FABRIZIO
To: SWEDISH ORPHAN BIOVITRUM AG
Reel/Frame 057369/0885 →
Continuity (5)
Provisional Application
62246949
· Oct 27, 2015
Provisional Application
62221393
· Sep 21, 2015
Provisional Application
62158153
· May 7, 2015
References Cited (210)
US 4522811A
· Eppstein et al.
· 1985
[cited by applicant]
US 4599306A
· Altrock
· 1986
[cited by applicant]
US 4727138A
· Goeddel et al.
· 1988
[cited by applicant]
US 5096705A
· Goeddel et al.
· 1992
[cited by applicant]
US 5859205A
· Adair et al.
· 1999
[cited by applicant]
US 6534059B2
· Skurkovich et al.
· 2003
[cited by applicant]
US 6558661B1
· Ashkenazi et al.
· 2003
[cited by applicant]
US 6861056B2
· Skurkovich et al.
· 2005
[cited by applicant]
US 7084257B2
· Desphpande et al.
· 2006
[cited by applicant]
US 7115263B2
· Skurkovich et al.
· 2006
[cited by applicant]
US 7183390B2
· Vasquez et al.
· 2007
[cited by applicant]
US 7335743B2
· Welcher et al.
· 2008
[cited by applicant]
US 7635473B2
· Warne et al.
· 2009
[cited by applicant]
US 7700098B2
· Ferlin et al.
· 2010
[cited by applicant]
US 9682142B2
· Ferlin et al.
· 2017
[cited by applicant]
US 20030059428A1
· Skurkovich et al.
· 2003
[cited by applicant]
US 20040052791A1
· Ehrhardt et al.
· 2004
[cited by applicant]
US 20070166307A1
· Bushell et al.
· 2007
[cited by applicant]
US 20100158922A1
· Ferlin et al.
· 2010
[cited by applicant]
US 20110123518A1
· Pipkin et al.
· 2011
[cited by applicant]
US 20110158987A1
· Adler et al.
· 2011
[cited by applicant]
US 20130142809A1
· Welcher et al.
· 2013
[cited by applicant]
US 20170189528A1
· Kaya et al.
· 2017
[cited by applicant]
US 20170291943A1
· Ferlin et al.
· 2017
[cited by applicant]
US 20170360929A1
· Sinha et al.
· 2017
[cited by applicant]
CN 101151277A
· 2008
[cited by applicant]
CN 104159919A
· 2014
[cited by applicant]
EP 0695189B1
· 1998
[cited by applicant]
EP 1401496B1
· 2006
[cited by applicant]
EP 0966300B1
· 2008
[cited by applicant]
JP 2011506538A
· 2011
[cited by applicant]
JP 2015505300A
· 2015
[cited by applicant]
KR 20100016001A
· 2010
[cited by applicant]
KR 20110125664A
· 2011
[cited by applicant]
WO WO00032634A1
· 2000
[cited by applicant]
WO WO03039485A2
· 2003
[cited by applicant]
WO WO03097082A2
· 2003
[cited by applicant]
WO WO2004035747A2
· 2004
[cited by applicant]
WO WO2004046306A2
· 2004
[cited by applicant]
WO WO2006109191A2
· 2006
[cited by applicant]
WO WO2007106811A2
· 2007
[cited by applicant]
WO WO2009080541A1
· 2009
[cited by applicant]
WO WO2010042705A1
· 2010
[cited by applicant]
WO WO2012022734A2
· 2012
[cited by applicant]
WO WO2013078378
· 2013
[cited by applicant]
WO WO2015190378A1
· 2015
[cited by applicant]
WO WO2016177913A1
· 2016
[cited by applicant]
WO WO2018078442A2
· 2018
[cited by applicant]
Schroepf et al., Inflamm Bowel Dis 2010;16:1882-1890. (Year: 2010).
[cited by examiner]
Campanati et al., Arch Dermatol Res (2014) 306:915-920. (Year: 2014).
[cited by examiner]
Collins et al., Arthritis and Rheumatism, (Oct. 2013) vol. 65, Supp. 10, pp. S687-S688. Abstract No. 1619. (Year: 2013).
[cited by examiner]
Ravelli et al. (Genes and Immunity (2012) 13, 289-298). (Year: 2012).
[cited by examiner]
Chen et al., “Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lessons,” Arch Dermatol Res, 302, pp. 113-123, Jun. 11, 2009.
[cited by applicant]
Jacqmin et al., “Innovative use of PK and PD to guide dose selection for a monoclonal antibody aimed at neutralizing the high IFNγ activity present in patients with macrophage activation syndrome (MAS)”, 2016 ACR/ARHP A…
[cited by applicant]
AIEOP presentation (Nov. 2012) “Studio di IFN-g come target di terapia: “FIGHT HLH”” NovImmune; 22 pages.
[cited by applicant]
AIEOP presentation (Nov. 2013) “Plasma levels of IFN-γ in hemophagocytic syndrome,” NovImmune; 20 pages.
[cited by applicant]
Allen, C. E. & McClain, K. L. (2015) “Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis,” Hematology Am Soc Hematol Educ Program, (1): 177-182 (2015).
[cited by applicant]
Anonymous (Jun. 10, 2010) “Public summary of opinion on orphan designation. Recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis” European Medicines Agency…
[cited by applicant]
Anonymous (Oct. 15, 2012) “European Commission awards EUR 6 million grant to ‘FIGHT HLH’” [online]. Novimmune.com: News Retrieved from the Internet: URL:https://www.novimmune.com/en/swiss-biopharmaceutical-company/news/…
[cited by applicant]
Anonymous (Mar. 16, 2015) “New drug begins testing as first-line treatment for fatal childhood disease” [online]. Novimmune.com: News. Retrieved from the Internet: URL:https://www.novimmune.com/en/swiss-biopharmaceutica…
[cited by applicant]
Aricò, M. et al. “Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry”
[cited by applicant]
Avau, A. et al. “Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant. Regulation by interferon-gamma”
[cited by applicant]
Baldrick, P. “Pharmaceutical excipient development: the need for preclinical guidance”
[cited by applicant]
Behrens, E.M. et al. “Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice”,
[cited by applicant]
Behrens, E.M. et al. “Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis”
[cited by applicant]
Bernsen, M.R. et al. (2003) “On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases”
[cited by applicant]
Bigler, J. et al., “Network analysis of psoriasis cytokine pathways after treatment with four different biological therapeutics or candidates,” British Journal of Dermatology, 171:e105, Poster Abstracts p. 61 (2014), 1 …
[cited by applicant]
Billiau, A. “Interferon-gamma: biology and role in pathogenesis”
[cited by applicant]
Bracaglia, C. et al. “Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in syst…
[cited by applicant]
Bracaglia, C. et al., “Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis,” Pediatric Rheumatology 2015 13(Suppl 1): O68, 2 p…
[cited by applicant]
Buatois, V. et al. (Dec. 2011) “A single dose of anti-mouse IFNg reduces key clinical and laboratory features of hemophagocytic lymphohistiocytosis (HLH) in a mouse model” Special Issue: Abstracts of the Annual Congress…
[cited by applicant]
Canna, S.W. et al. “An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome”,
[cited by applicant]
Charman, W.N. “Lipids, lipophilic drugs, and oral drug delivery some emerging concepts”
[cited by applicant]
Chothia, C. et al., “Conformations of immunoglobin hypervariable regions”
[cited by applicant]
clinicaltrials.gov (Mar. 8, 2015) “View of NCT01818492 on Mar. 8, 2015. A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis” [online]. R…
[cited by applicant]
Davì, S. et al. “Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis”
[cited by applicant]
De Benedetti, F. et al. “Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis”
[cited by applicant]
De Benedetti, F. et al. “Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis”
[cited by applicant]
De Jager, W. et al. “Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study”
[cited by applicant]
De Min, C. et al. (Sep. 2, 20159) “Innovative Approach for the Identification of an Appropriate Dose Regimen of a Targeted Treatment, NI-0501, an Anti-Interferon Gamma (IFNg) Antibody, in Patients with Hemophagocytic Ly…
[cited by applicant]
De Min, C. et al. “IFNy drives disease in the TLR9-mediated secondary hemophagocytic lymphohistiocytosis (sHLH) in mice. Rationale for a new therapeutic target in secondary HLH secondary to infection in humans”,
[cited by applicant]
Dhote, R. et al. “Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review”
[cited by applicant]
Duarte, G.V. et al. “Osteopontin, CCL5 and CXCL9 are independently associated with psoriasis, regardless of the presence of obesity”
[cited by applicant]
Fall, N. et al. “Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrom…
[cited by applicant]
Fardet, L. et al. “Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome”
[cited by applicant]
Filipovich, A. “Hemophagocytic lymphohistiocytosis (HLH) and related disorders”,
[cited by applicant]
Filipovich, A. et al. “Histiocytic disorders: recent insights into pathophysiology and practical guidelines”
[cited by applicant]
Gao, Y. et al. (Aug. 4, 2003) “γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity”
[cited by applicant]
Genbank Accession No. M997660.1 (Oct. 17, 2007) “Human immunoglobulin heavy chain variable region V3-23 (IGHV@) gene, exons 1-2” National Center for Biotechnology Information (NCBI) [online]. Retrieved from: http://www.…
[cited by applicant]
Genbank Accession No. X13274 (Nov. 15, 1994) “Human mRNA for interferon IFN-gamma” National Center for Biotechnology Information (NCBI) [online]. Retrieved from: http://www.ncbi.nlm.nih.gov/nuccore/32691; retrieved on J…
[cited by applicant]
Genbank Accession No. Z73673.1 (Sep. 9, 2004) “
[cited by applicant]
Goldsby, R.A et al.
[cited by applicant]
González-Cabañas, R. et al. (1998) “Inmunogenicidad del interferon alfa-2b recombinante (Heberón alfa R®). Detección de anticuerpos mediante un ensayo inmunoenzimático y neutralización de actividad antiviral”
[cited by applicant]
Goswami, S. et al., “Developments and Challenges for mAb-Based Therapeutics,” Antibodies, 2:452-500 (2013).
[cited by applicant]
Green, D.S. et al. (Jun. 7, 2004) “IgG-derived Fc Down-regulates virus-induced plasmacytoid dentritic cell (pDC) IFNα production”
[cited by applicant]
Grom, A.A. et al. “Macrophage activation syndrome in the era of biologic therapy”
[cited by applicant]
Groom, J.R. et al. “CXCR3 ligands: redundant, collaborative and antagonistic functions”,
[cited by applicant]
Harden, J. (2015) “Humanized anti-IFN-γ(HuZAF) in the treatment of psoriasis”
[cited by applicant]
Harrington, L. E. et al., “Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages,” Nature Immunology, 6(11):1123-1132 (2005).
[cited by applicant]
Hashkes, P.J. et al., “Mortality outcomes in pediatric rheumatology in the US”
[cited by applicant]
Henter, J-I. et al. “HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis”
[cited by applicant]
Henter, J-I. et al. “Hypercytokinemia in familial hemophagocytic lymphohistiocytosis”,
[cited by applicant]
Henter, J-I. et al. “Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis”
[cited by applicant]
Henter, J-I. et al. “Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation”
[cited by applicant]
HLH-2004, “Treatment Protocol of the Second International HLH Study 2004,” pp. 1-36, Jan. 2004.
[cited by applicant]
Horne, A. et al. “Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis” Br J Haematol, vol. 129, p. 622-630 (2005).
[cited by applicant]
Imashuku, S. et al. “Hyper-interleukin (IL)-6-naemia in haemophagocytic lymphohistiocytosis”,
[cited by applicant]
Janka, G.E. “Familial hemophagocytic lymphohistiocytosis”
[cited by applicant]
Janka, G.E. et al. “Hemophagocytic lymphohistiocytosis: pathogenesis and treatment”
[cited by applicant]
Jordan, M.B. “An animal model of hemophagocytic lymphohistiocytosis (Hlh): CD8+ T cells and interferon gamma are essential for the disorder”,
[cited by applicant]
Jordan, M.B. et al. “How I treat hemophagocytic lymphohistiocytosis”, Blood, vol. 118, No. 15, p. 4041-4052 (2011).
[cited by applicant]
Jordan, M. et al., Abstract. “A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Ph…
[cited by applicant]
“Juvenile Rheumatoid Arthritis” [online]. Retrieved from: https://www.stanfordchildrens.org/en/topic/default?id =juvenile-rheumatoid-arthritis-90-P01722; downloaded Jul. 19, 2019, 4 pages (2019).
[cited by applicant]
Kakuta, S. et al. (Jan. 2002) “Inhibition of B16 melanoma experimental metastasis by interferon-γ through direct inhibition of cell proliferation and activation of antitumour host mechanisms”
[cited by applicant]
Kaufman, K.M. et al. “Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis”
[cited by applicant]
Kögl, T. et al. “Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease”
[cited by applicant]
Kitgo, C. L. et al., “Plasma CXCL9 elevations correlate with chronic GVHD diagnosis,” Blood, 123(5):786-793 (2014).
[cited by applicant]
Lasiglie, D. et al. “Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients”,
[cited by applicant]
Lehmberg, K. et al. “Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis”
[cited by applicant]
Lin-Hua, J. et al., “Increment of chemokine CXCL9/Mig in plasma correlated with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, 14(6):1200-3…
[cited by applicant]
Marasco et al., “Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gpl20 single-chain antibody”
[cited by applicant]
Maruoka, H. et al. (2014) “IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome”
[cited by applicant]
Mavilia, C. et al. (Dec. 1997) “Type 2 Helper T-Cell Predominance and High CD30 Expression in Systemic Sclerosis”
[cited by applicant]
Miller, Brady et al. “Hemophagocytosis in adults (Hemophagocytic Syndrome)” University of Washington PowerPoint Presentation [online]. Retrieved from the Internet: URL:http://depts.washington.edu/hemeweb/seminarsconfere…
[cited by applicant]
Min, C. D. et al. 2015 ACR/ARHP Annual Meeting, Sep. 29, 2015, Abstract No. 3097, 2 pages.
[cited by applicant]
Minoia, F. et al. “Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients”
[cited by applicant]
Minoia, F. et al. “Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis”
[cited by applicant]
Momblona, S. (1999) “Cuarenta Años de Interferones”
[cited by applicant]
Moradinejad, M.H. et al. “The incidence of macrophage activation syndrome in children with rheumatic disorders”
[cited by applicant]
My, L.T. et al. “Comprehensive analyses and characterization of haemophagocytic lymphohistiocytosis in Vietnamese children”
[cited by applicant]
Nemunaitis, J. et al. (2000) “Long-term follow-up of retroviral vector-administered interferon-γ(IFN-γ) gene in metastatic melanoma”
[cited by applicant]
Nicolaidou, V. et al. (2015) “Gene expression changes in HLA mismatched mixed lymphocyte cultures reveal genes associated with allorecognition” Tissue Antigens, 85:267-277.
[cited by applicant]
Ogilvie, E.M. et al. “Specific gene expression profiles in systemic juvenile idiopathic arthritis”
[cited by applicant]
Ortmann, R. A. & Shevach, M., “Susceptibility to Collagen-Induced Arthritis: Cytokine-Mediated Regulation,” Clinical Immunology, 98(1):109-118 (2001).
[cited by applicant]
Padlan, E. (1994) “Anatomy of the Antibody Molecule”
[cited by applicant]
Pascual, V. et al., “Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade”
[cited by applicant]
Perrier, C. et al. (2011) “Cytokine blockade in inflammatory bowel diseases”
[cited by applicant]
Petty, R.E. et al. “International League of Associations for Rheumatology classification of juvenile idiopathic arthritis, second revision, Edmonton, 2001”,
[cited by applicant]
Portolano, S. et al. (Feb. 1, 1993) “Lack of Promiscuity in Autoantigen-Specific H and L Chain Combinations as Revealed by Human H and L Chain Roulette” J Immunol, 150(3):880-887.
[cited by applicant]
Powell, M.F. et al. “Compendium of excipients for parenteral formulations”
[cited by applicant]
Put, K. et al. “Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ”
[cited by applicant]
Ramanan, A.V. et al. “Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis”
[cited by applicant]
Ravelli, A. et al., “Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment”
[cited by applicant]
Reinisch, W. et al. (2006) “A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderat…
[cited by applicant]
Risdall, R.J. et al. “Bacteria-associated hemophagocytic syndrome”
[cited by applicant]
Risdall, R.J. et al. “Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis” Cancer, vol. 44, p. 993-1002 (1979).
[cited by applicant]
Risma, K. “Hemophagocytic lymphohistiocytosis: updates and evolving concepts”,
[cited by applicant]
Ruperto, N. et al. “Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis”,
[cited by applicant]
Sawhney, S. et al. “Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders”
[cited by applicant]
Schoenborn, J.R. et al. “Regulation of interferon-gamma during innate and adaptive immune responses”
[cited by applicant]
Schulert, G.S. et al. “Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies”,
[cited by applicant]
Schmid, J.P. et al. “Neutralization of IFN[gamma] defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice”
[cited by applicant]
Sepulveda, F.E. et al. “Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11”,
[cited by applicant]
Shimizu, M. et al. “Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis”
[cited by applicant]
Sigidin, Y.A. et al. (2001) “Randomized, Double-Blind Trial of Anti-Interferon-Gamma Antibodies in Rheumatoid Arthritis”
[cited by applicant]
Sikora, K.A. et al. “The limited role of interferon-gamma in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness”
[cited by applicant]
Skurkovich, B. and S. Skurkovich (2003) “Anti-Interferon-Gamma Antibodies in the Treatment of Autoimmune Diseases”
[cited by applicant]
Stéphan, J.L. et al. “Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients”
[cited by applicant]
Stern, A. et al. “Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy”,
[cited by applicant]
Strippoli, R. et al. “Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome”,
[cited by applicant]
Takada, H. et al., “Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis”,
[cited by applicant]
Tang, Y. et al. “Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome”,
[cited by applicant]
Todak, A. (Dec. 8, 2015) “Novel treatment provides less toxic approach for pediatric HLH management” Highlights from ASH, Meeting News Coverage: Jordan, M. et al. Abstract LBA-3. Presented at: ASH Annual Meeting and Exp…
[cited by applicant]
Trottestam, H. et al. “Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol”,
[cited by applicant]
Usmani, G. N. et al. “Advances in understanding the pathogenesis of HLH,”
[cited by applicant]
Vastert, S.J. et al. “Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis”
[cited by applicant]
Wallace, C.A. et al. “Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis”
[cited by applicant]
Wang, W. “Lyophilization and development of solid protein pharmaceuticals”
[cited by applicant]
Wang, W. et al., “Antibody Structure, Instability, and Formulation, Journal of Pharmaceutical Sciences,” 96(1), Jan. 2007; published online in Wiley Interscience www.interscience.wiley.com; doi: 10.1002/jps.20727, 26 pa…
[cited by applicant]
Werth, V. P. et al., “A Phase I Single-Dose Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of AMG 811 (anti-IFN-gamma) in Subjects With Discoid Lupus Eryt…
[cited by applicant]
Wiendl, H. et al. (2002) “Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials”
[cited by applicant]
Willenborg, D. O. et al., “IFN-γ Is Critical to the Control of Murine Autoimmune Encephalomyelitis and Regulates Both in the Periphery and in the Target Tissue: A Possible Role for Nitric Oxide,” J Immunol, 163:5278-528…
[cited by applicant]
Xu, X.J. et al. “Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children”
[cited by applicant]
Yamamoto, K. (Aug. 2003) “Chapter XVI.2. Juvenile Rheumatoid Arthritis” Case Based Pediatrics for Medical Students and Residents. Department of Pediatrics, University of Hawaii John A. Burns School of Medicine; 7 pages.
[cited by applicant]
Zhang, K., et al., “Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms”
[cited by applicant]
Zhang, M. et al. “Genetic defects in cytolysis in macrophage activation syndrome”,
[cited by applicant]
Zhang, S.Y. et al. (2008) “Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense”
[cited by applicant]
Zhuang, J. et al., “CXCL9 and CXCL10 accelerate acute transplant rejection mediated by alloreactive memory T cells in a mouse retransplantation model,” Experimental and Therapeutic Medicine, 8:237-242 (2014).
[cited by applicant]
Zoller, E.E. et al. “Hemophagocytosis causes a consumptive anemia of inflammation”
[cited by applicant]
De Benedetti et al., “Efficacy and safety of emapalumab in macrophage activation syndrome,” Ann Rheum Dis., (Jun. 2023), 82(6):857-865.
[cited by applicant]
Gamifant(TM) (emapalumab-Izsg) injection, Medication Guide for intravenous use, Highlights and Prescribing Information. Initial U.S. Approval: 2018 (Nov. 2018) Reference ID: 4352133, pp. 1-17.
[cited by applicant]
Grom et al., “Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Disease…
[cited by applicant]
Prencipe et al., “Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome,” J Allergy Clin Immunol., (Apr. 2018) 141(4):1439-1449.
[cited by applicant]
Rosenblum et al. “CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors,” J Immunol. (Apr. 2010) 184(7):3450-3460.
[cited by applicant]
Shim H., One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med. 2011, vol. 43, No. 10, p. 539-549.
[cited by applicant]
Sieni et al. “Familial hemophagocytic lymphohistiocytosis: when rare diseases shed light on immune system functioning,” Front Immunol. (Apr. 16, 2014) 5:167, 19 pages.
[cited by applicant]
Bracaglia C., et al.; “Interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model,” Pediatric …
[cited by applicant]
ClinicalTrials.gov ID NCT02069899: “A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody…
[cited by applicant]
Daugherty et al., “Formulation and delivery issues for monoclonal antibody therapeutics,” Adv Drug Deliv Rev., (Aug. 2006); 58(5-6):686-706.
[cited by applicant]
Nigrovic, P.A.; “Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis,” Proc Natl Acad Sci USA (2015); 112(52):15785-15786.
[cited by applicant]
Boedigheimer et al., “Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis”, Lupus Science & Medicine, 2017; 4(1);e000226, 9…
[cited by applicant]
Murry et al., “Contrasting Cytokine Profiles in the Synovium of Different Forms of Juvenile Rheumatoid Arthritis and Juvenile Spondyloarthropathy: Prominence of Interleukin 4 in Restricted Disease”, The Journal of Rheum…
[cited by applicant]
Pernice et al., “Therapy for systemic juvenile rheumatoid arthritis with γ-interferon: A pilot study of nine patients”, Arthritis Rheumatism, vol. 32, No. 5 (May 1989);643-646.
[cited by applicant]
Bracaglia, C., et al.; “Interferon-Gamma (IFNg) in Macrophage Activation Syndrome (MAS): CXCL9 Levels as a Biomarker for IFNg Production in MAS,” Abstract No. 3096; Meeting: 2015 ACR/ARHP Annual Meeting (Sep. 29, 2015);…
[cited by applicant]
Office Action for JP Application No. 2023-078474, dated Nov. 8, 2024, with English translation, 8 pages.
[cited by applicant]
Uchiyama, S., et al., “Solution properties of antibody drugs,” Journal of Pharmaceutical Science and Technology, Japan, 2014, 74(1), pp. 12-18.
[cited by applicant]
Warne, N.W., et al., “Development of High Concentration Protein Biopharmaceuticals: The Use of Platform Approaches in Formulation Development,” European Journal of Pharmaceutics and Biopharmaceutics, Jun. 2011, vol. 78(…
[cited by applicant]